• Molecular NameEprosartan
  • SynonymNA
  • Weight424.521
  • Drugbank_IDDB00876
  • ACS_NO133040-01-4
  • Show 3D model
  • LogP (experiment)4.283
  • LogP (predicted, AB/LogP v2.0)4.26
  • pka5.3
  • LogD (pH=7, predicted)0.52
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.52
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds10
  • TPSA120.66
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn angiotensin II receptor antagonist used for the treatment of high blood pressure.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability13.0
  • Protein binding98.6
  • Volume of distribution (VD)0.16
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmnot metabolized
  • Half life5~9 h
  • ExcretionRenal 10%, biliary 90%
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThere was no mortality in rats and mice receiving oral doses of up to 3000 mg eprosartan/kg and in dogs receiving oral doses of up to 1000 mg eprosartan/kg.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A